SB-747651A (dihydrochloride)

$220$1,850

Products Details

Product Description

– SB-747651A dihydrochloride is an ATP-competitive mitogen- and stress-activated kinase 1 (MSK1) inhibitor with an IC50 of 11 nM. SB-747651A dihydrochloride also inhibits PRK2, RSK1, p70S6K and ROCK-II. SB-747651A dihydrochloride can be used for inflammation research[1].

Web ID

– HY-110313

Storage Temperature

– 4°C (Powder, sealed storage, away from moisture)

Shipping

– Room Temperature

Applications

– COVID-19-immunoregulation

Molecular Formula

– C16H24Cl2N8O

References

– [1]Shaista Naqvi, et al. Characterization of the cellular action of the MSK inhibitor SB-747651A. Biochem J. 2012 Jan 1;441(1):347-57.|[2]Feiner B, et al. Risperidone effects on heterochromatin: the role of kinase signaling. Clin Exp Immunol. 2019;196(1):67-75.|[3]Hossain M, et al. The Specific Mitogen- and Stress-Activated Protein Kinase MSK1 Inhibitor SB-747651A Modulates Chemokine-Induced Neutrophil Recruitment. Int J Mol Sci. 2017;18(10):2163. Published 2017 Oct 17.

CAS Number

– 1781882-72-1

Molecular Weight

– 415.32

Compound Purity

– 99.0

SMILES

– NC1=NON=C1C(N2CC)=NC3=C2C(CNC4CCNCC4)=CN=C3.[H]Cl.[H]Cl

Clinical Information

– No Development Reported

Research Area

– Inflammation/Immunology

Solubility

– H2O : 50 mg/mL (ultrasonic)

Target

– p38 MAPK

Pathway

– MAPK/ERK Pathway

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=